David J. McConkey of Johns Hopkins Greensberg Bladder Cancer Institute explains why some bladder cancer subtypes respond to immunotherapy and others do not at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Advertisement
Advertisement